Join our daily newsletter At The Bell to receive exclusive market insights
- AVITA Therapeutics (AVH) has enrolled the first vitiligo patient in its pivotal study evaluating the use of its RECELL System to assist with repigmentation
- Vitiligo is an autoimmune disease that attacks the epidermis, the outer layer of the skin, and leads to the loss of pigmentation
- The clinical study, in patients who have not seen a worsening of their condition for one year, is evaluating the safety and effectiveness of the RECELL System to restore colour to skin lesions
- AVITA’s RECELL system is already used to treat burns and does so by creating Spray-On-Skin Cells from a small sample of the patient’s skin
- The regenerative medicine company will also carry out a vitiligo feasibility study in partnership with the University of Massachusetts Medical School
- Shares gained 2.78 per cent today to close at $7.40
AVITA Therapeutics (AVH) has enrolled the first patient in its pivotal study assessing the use of its RECELL System in treating vitiligo.
Vitiligo is an autoimmune disease that attacks the epidermis, the outer layer of the skin, and leads to the loss of pigmentation.
The clinical study, in patients whose vitiligo has been stable for one year, is being carried out at multiple sites across the United States, with the first patient recruited at the Miami Dermatology and Laser Institute.
The trial will assess both the safety and effectiveness of the AVITA RECELL System in repigmentation of the skin at 24 weeks.
The system is already used to treat burns and works by creating Spray-On-Skin Cells from a small sample of the patient’s cells.
AVITA Therapeutics’ CEO Dr Mike Perry said the recruitment of the first trial participant represents a significant milestone for the company.
“The initiation of the vitiligo clinical study is a milestone in advancing AVITA Therapeutic’s pipeline to leverage the utility and full potential of our innovative RECELL technology platform to address unmet medical needs in dermatological applications,” Dr Mike said.
“Globally, there have been several published case series and pilot randomized clinical trials reporting positive results with the use of RECELL for treating patients with stable vitiligo and repigmenting depigmented skin lesions. We are pleased to initiate this pivotal study as a next step toward offering a treatment option for the millions of Americans who live with vitiligo,” he added.
The regenerative medicine company will also carry out a vitiligo feasibility study in partnership with the University of Massachusetts Medical School.
Shares gained 2.78 per cent today to close at $7.40.
